Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis

Mesalamine (5-ASA) is the mainstay therapy in patients with mild-to-moderate active ulcerative colitis (UC). However, non-adherence to therapy and practice variability among gastroenterologists represent long-standing barriers, leading to poor outcomes. Additionally, targets to treat in UC are incre...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Clin Med
Main Authors: Solitano, Virginia, D’Amico, Ferdinando, Fiorino, Gionata, Paridaens, Kristine, Peyrin-Biroulet, Laurent, Danese, Silvio
Format: Artigo
Jezik:Inglês
Izdano: MDPI 2020
Teme:
Review
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7564568/
https://ncbi.nlm.nih.gov/pubmed/32911840
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm9092905
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki